Showing results (211-220 of 252) with videos related to

Sort By:
Pageof 26
Blood Advances|July 30, 2020
A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCLZijun Y Xu-Monette, Hongwei Zhang, Feng Zhu, et al.
Journal for Immunotherapy of Cancer|October 24, 2019
Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapiesZijun Y Xu-Monette, Jianyong Li, Yi Xia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2022
Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell LymphomaZijun Y Xu-Monette, Li Wei, Xiaosheng Fang, et al.
Oncotarget|November 18, 2015
Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphomaQing Ye, Zijun Y Xu-Monette, Alexandar Tzankov, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 8, 2010
A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTRHillard M Lazarus, Mei-Jie Zhang, Jeanette Carreras, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2014
Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphomaChi Young Ok, Jiayu Chen, Zijun Y Xu-Monette, et al.
Aging|December 13, 2016
RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphomaMingzhi Zhang, Zijun Y Xu-Monette, Ling Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 20, 2023
Tumor-Infiltrating Normal B Cells Revealed by Immunoglobulin Repertoire Clonotype Analysis Are Highly Prognostic and Crucial for Antitumor Immune Responses in DLBCLZijun Y Xu-Monette, Yong Li, Thomas Snyder, et al.
Journal of Hematology & Oncology|November 5, 2020
XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53Manman Deng, Mingzhi Zhang, Zijun Y Xu-Monette, et al.
Oncoimmunology|August 5, 2021
Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphomaHua You, Zijun Y Xu-Monette, Li Wei, et al.
Pageof 26